Support
2019
1399
20 –
-2019
2
2019 COVID-19
(
COVID-19
8
) .
–1 -2 -3 -4 -5 -6 -7 -8
3
-2019
-1 1425
19 800
.
-1 :
N95
-2
). (98 -3 (98
). -4 (98
). -5 (98
(
)
):
52
9 .(99
-
). 2
-
.(99 32 .( .(98 .(98
) )
) 5
-
7
-
5
-
)
2 ) .(99
-
4
-2019
-6 .(98
)
A
15
CT
-7
.(99
) -8
.(98
) -9
).
Remdesivir
.(99 7 .(
)
-10 Favipiravir Remdesivir
-11
Can FAH
).
Valve
.(99 -12 .(98
)
3
-13 .(99
) -14
.(98
)
10 -15
.(99
) -16 .(98) .
.
-17 .(
) -18
.(
)
5
-2019
-19 .(99 .(98
)
)
-20 -21 .(99
) -22
UV
.(
)
)
-23 .( 100
-24
Favipiravir
-25
. .(
) -26
.
Valve Can
-27 .(
). -28
.(
)
1000 -29
N95
/ -30
-31 ....
-2019
6
-32 . -33
PMS
-34
-35 -36 . -37 -38 -39 -40 -41
RNA/DNA
-42 -43 9 -44
-1
RNA DNA (VLP)
-2
ReNap Co
8
-3
7
-2019
-4 -5 :
: : -
ReNap
: -
Cell Tech
o o o
-46
CT
-47 8
-48 -49 -50
-2019
8
-51 -55 -56 -57 -58 -59 -60 -61 -62
CT
:
. .
...
-2 rtPCR
9
-2019
39 .
-3 -3-1 19:
19. . . : COVID 19
19
.1 .2 .3 .4 .5 )
19
.6 (.... 19
19
.7 .8 .9
10
-2019
.10 19
.11 .12
ICU
)
.13 (...
ICU
.14 .15 .16 -
)
.17 nested case-control
(.....
19
.18
-1 -2 -3 19
-4 -5 -6 -7 -8
:19 19
200 . .
. .
11
-2019
. .
. :
.
(nimadiran@gmail.com)
(Registry.behdasht.gov.ir)
/
-3-2 19
/ 19
.
)
12
-2019
:1
.(2 19
.
)
86
1
. . .
.
.
. .
.
.
17 7
3
) 90
1
. )
.(
. .
.
Global Research Collaboration for Infectious Disease Preparedness
(
GLOPID-R
13
-2019
http://nimad.ac.ir/content/200/COVID-19
.
(
) 1 19-
. Strengthening system, Improving the Public’s Health, National Public
.
Health Performance Standards Program
.
(
) :
.1 (
)
(
.2
)
.3
.
.4
:
.1 .(
) .2
.
.3 .
.4
.
(
) .5 . .
14
-2019
. .
-4 - SOLIDARITY 19
4 -
(
19
4
:(SOLIDARITY
)
-
(2 Remdesivir (1
. +
2500
.(2020
(1
(
+ 24)
(4
19
7)
(3
+
.
(2020
22)
.
30
405
11266
3500 (
) (Interim analysis) .
**
19**
) :
(
Remdesivir RR=0.95 (0.81-1.11, p=0.50; 301/2743 active vs 303/2708 control) Hydroxychloroquine RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906) Lopinavir RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372)
15
-2019
Interferon RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050)
596 2
SOLIDARITY
5257
. 3
2462 .(
99
1399
18
3
2462
) -
50
3
-
45
3
38
3
38 -
)
RCT
3
2 2
-
18
RCT
3
)
) -
32 31
https://covid19.trialstracker.net/ accessed November 08, 2020 https://www.covid-trials.org/ accessed November 08, 2020
-
16
-2019
2
25
2
24
2
21
2
18
2
17
2
14
2
12 -
2
11
2
-
11
2
-
10
-
1
9
1
8
1
8
1
8
1
8
1
8
1
7
1
7
1
7
1
7
1
5
1
5
1
4
1
-
4
1
-
4
-
1
4
1
4
1
3 -
1
1
-
12
2
1
-
-
3 3
-
3
-
-
17
1
-2019
3
1
-
3
PHR
)
)
-
(Remdesivir) (Tocilizumab)
(Quercetin)
+(
C
)
)
–
(IFN -1b)
(Sambucus nigra)
)
+
1-
(IFN -1a) 1-
)
( (
) ) + + +
(IVIG)
+ Zofa
(Salix)
(Artemisia)
+
18
-2019
) ) +
(
) )
)
(
)
Tenofovir ANIF1
Stopcivir
7MMF
– + + (
+
)
(.Ficus Carica L) +
+ D C
)
+
+
+
+
/
+
+
+
C
+
+
+ (
+
+
Oseltamivir
)
+
+
AB7
+
Cyclotide complex Myrtus® Active Hexose
+
+
AHCC)
+
(Correlated Compound ( ) (CURCUDEN)
+
/
+
/
+ + +
+
+ +
Anval SZ
1-
+
+
+
+ + +
19
) (Jollab)
-2019
/
(
1
+ +
– -
+ (
-
+
fennel - terminalia chebula
(
)
/
+
/
+
/
(Sofosbuvir+Ledipasvir)
)
(Sofosbuvir/Velpatasvir) Tranilast +Tranilast
+
Borage based
+
+
-
(HEP1)
(
Hep-S
) SNP
BCc1
colloide silver nasal spray 10ppm
(
8
) -
)
(
+
MAB98 Trachyspermum ammi Colchicum autumnale
(Phoenix dactylifera)
Nigella sativa
(tPA) (Edaravone)
20
-2019
Grapex
(prebiotic)
LactocareÂŽ
)
C
(
(DMSO)
)
0/2 -
N
-
(hymecromone)
C
+
A A, D, E, C, B D C B (25OHD) N
cold atmospheric plasma Convalescent Plasma
D3
-
zinc C D
) ( NK Placental stromal cell
3
(SVF)
-
GCSF
+C
(
-
+ +
)
(Ipecac)
. . MMR
(PPD)
21
-2019
(BER) «
» COVID-19
(PDT)
19
(Photobiomodulation)
( IRCT20160131026298N2) COVID-19 (IRCT20200325046860N1) 19:19-
PHR
(Oseltamivir
(IRCT (IRCT
(IRCT )
)
19: 19
(
(
19-
)
.5 .6
) 19 (IRCT
+
.4
D C
(IRCT
+
)
)
.1 .2 .3
.7
) 19
.8
(IRCT20200325046860N2) 19 -
(
)
.9
(IRCT20200318046812N1) )
.10
22
-2019
19
( IRCT
19
(
19
)
.11
(IRCT20200318046812N2)
(IRCT20080901001165N59) 19(IRCT20080901001165N48) 19 ) 19-
Zofa
(IRCT20080901001157N16)
(IRCT20080901001165N46) 19(IRCT20160131026298N5) 19-
(IRCT
(IRCT20080901001165N49) 19-
)
(IRCT20180129038542N1) 19(IRCT20191125045492N2) 19 (IRCT20171105037262N4) 19( ) anti-TNF(IRCT ) " + + " " + + + " (IRCT ) (IRCT20080901001165N51) covid19 ( ) 19(IRCT20080901001165N50) 19: 19 -
19 -
19-
(CoviGlobulin (CG
.12 .13 .14 .15 .16 .17 .18 .19 .20 .21 .22
Covid-19
"
+
.23
" +
" 19-
+
" .24 .25
(IRCT20080901001165N52) (IRCT20200508047346N1)
(IRCT20080901001165N58) 1919 1 ( ) (IRCT20080901001165N53,IRCT20200511047396N1) (N-acetyl cysteine)NAC (IRCT20080901001165N55) (IRCT20080901001165N60) 19(IRCT20080901001165N56)
.26 .27 .28 .29 .30 .31 .32
23
(IRCT
(IRCT20200509047373N1) 19 -
)
-2019
19-
(IRCT
) 19-
(IRCT
) 19-
19-
Cyclotide complex
(IRCT
) COVID-19
T
(
T
(
AB7
Glycyrrhizin
)
19-
(IRCT20160131026298N4) 19-
) COVID-19
(IRCT
19
19) 1399
(IRCT
(IRCT
1398 )
.34 .35
( IRCT20160131026298N5,IRCT20160131026298N6,IRCT20160131026298N3) ( IRCT20160131026298N6) 197(IRCT ) 19MMF 19Myrtus® (IRCT20080901001165N63) 192 (IRCT ) ) 19zinc C D (IRCT (IRCT ) 19-
(IRCT )
.33
( )
) 19
.36 .37 .38 .39 .40 .41 .42 .43 .44 .45 .46 .47 .48 .49 .50
(19-
) (19-
(IRCT20100228003449N28) COVID-19 (IRCT20100228003449N27) COVID-19
)
(Sofosbuvir/Daclatasvir) (IRCT20200128046294N2)
.1
.2 (IRCT20200322046833N1) 1399-1398 (IFN -1a) 1.3 (IFN -1b) 1.4
-2019
24
/
+
+
(IRCT20100228003449N29) COVID-19 COVID-2019
(IRCT20100228003449N30) COVID-19 / Remdesivir
(IRCT20171122037571N2)
-covid-19
(IRCT20120826010664N6) Placental stromal cell
COVID-19
(
)
(IRCT20200413047063N1)
.5 .6 .7 .8 .9 .10
(IRCT20180712040449N2) 2019 ( 44 1 ) .11 (IRCT20150914024017N1) .12 (19) 2019(IRCT20151113025025N3) 1399-1398 .13 (IRCT ) 19 Anti TNF.14 (IRCT20200312046749N1) -19(IRCT20200324046847N1) COVID 19 SEPTIMEB TM .15 COVID-19 ) .16 (IRCT20200404046947N1) :( :( COVID-19 ) .17 (IRCT20081027001411N3) COVID-) C .18 (IRCT20190917044805N2) :(19 : COVID-19 (25OHD) .19 (IRCT20200401046909N1,IRCT20200401046909N2) NK 21 .20 (IRCT20200417047113N1) Covid-19 ) .21 (IRCT 19.22 (IRCT20200411047025N1) : ( ) A, D, E, C, B .23 (IRCT20200319046819N1)
25
-2019
.24 COVID-19
(IRCT
(IRCT20200402046923N1)
) COVID- 19 COVID-19
(IRCT
)
(IRCT
19-
moderate intensity
(IRCT
) COVID-19
) 99
Covid 19
(IRCT
19-
(IRCT20200415047092N1)
)
:
COVID19
(IRCT20190717044241N2) COVID-19
Umifenovir
(IRCT20200523047550N1)
:(19-
)
) 2019
)
Covid-19
(IRCT
)
(IRCT
(IRCT
)
:( COVID-19
COVID-19
COVID-19
COVID-19
.32
.36
)
D
) 19-
.31
.35
Plasma Therapy Convalescent
(IRCT
.30
.34
) 99
(IRCT
19
)
( ) (IRCT
.27 .28 .29
.33
COVID-19
(IRCT
.25 .26
(IRCT ) (Actemra) Tocilizumab (IRCT20081027001411N4) :( COVID-19 ) (IRCT20200509047360N1)
.37 .38 .39 .40 .41 .42 .43
(IRCT20170211032494N3) 3 .44 ((IRCT20200511047399N1
26
-2019
(AHCC)
COVID-19
(IRCT
)
.45
:
– 19(IRCT
)
(IRCT
(IRCT20091201002804N12)
)
:
19-
.5 .6
Hydroxychloroquine
:
COVID-19
(IRCT20130917014693N10)
COVID-19
(
COVID-19
)
-
(
(IRCT20180923041093N5)
)
((IRCT20151227025726N15
(MSCs)
(IRCT20200421047150N1) (IRCT ) COVID-19 COVID-19
`
`
(IRCT
)
(IRCT
)
COVID-19
-1398
) 19
19
:COVID-19
.9
COVID-19
19-
(IRCT
.8
.12
Hydroxychloroquine
:
.7
.10 .11
(COVID-19 (IRCT20200711048076N1 COVID-19
.2 .3 .4
(COVID-19 (IRCT20151227025726N14
19
COVID-19
(IRCT20200328046882N1)
-
COVID-19
.1
(IRCT20200416047099N1 ) 2019
(IRCT20200428047228N1) 19(IRCT20200516047468N1) 1399 (IRCT20200428047228N2)
19(IRCT20200509047366N1)
.13 .14 .15 .16 .17 .18 .19
27
-2019
COVID-19
(IRCT20180923041093N6)
19-
(IRCT
(IRCT20170128032241N3) COVID-19
(IRCT
(IRCT
)
)
(IRCT
)
:ICU
CURCUDEN®
) 19-
Oseltamivir Umifenovir
19
(
)
COVOID-19
( )
(IRCT20200608047686N1)
19
(IRCT20200607047682N1) (IRCT20190131042569N5) (PDT)
19
(IRCT
)
(IRCT )
)
(19
ICU
:
+ (IRCT (IRCT
19+
(A ) (IRCT ) Covid-19 ) COVID-19 (IRCT ) COVID-19 ) 19-
)
) ) Covid- 19 (IRCT /
3
(B
(prebiotic)
COVID-
(IRCT
(IRCT
) 19-
:
«
) 19
(IRCT20200323046841N1)
(nCov-2019)
/
+
/
)
3
(IRCT20200325046859N1) (IRCT
)
.22 .23 .24 .25 .26 .27 .28
.30 .31 .32 .33 .34 .35 .36 .37 .38
.1
»
.2
IVIg
(
.21
.29
Open Label
(IRCT
.20
COVID-19
.3
28
-2019
(IRCT20081019001369N2) 2019 (Sambucus nigra)
2019
(IRCT20200404046933N1)
(IRCT20081019001369N3) 2019 (IRCT20081019001369N4) (19) 2019 (IRCT20200408046990N1)
(IRCT20200406046965N1)
:
–
(
)
(COVID-19)
COVID-19
(IRCT
(IRCT
)
) 19
(IRCT20200413047053N1) 19
(COVID-19 (IRCT20200409047007N1
: COVID-19
-
COVID-19
(IRCT20200408046990N2)
(IRCT20200405046958N1) colchicine
:
19-
(IRCT20170922036314N4) (IRCT20191228045924N1) (19) 2019 (19) 2019
COVID-19
(IRCT20200408046990N3) ) COVID-19
(IRCT20081019001369N5) (IRCT20160809029275N1) 19
(IRCT
4
) COVID-19
(IRCT20161206031256N3)
-
(
:
/ ;2019
+ (
) 2019
/
)
/
3
(IRCT
(IRCT20110726007117N11) COVID-19
(IRCT20081019001369N6) (19-
/
Lactocare
(IRCT20101020004976N6)
.6 .7 .8 .9 .10 .11 .12 .13 .14 .15 .16
:
(IRCT20150716023235N15) 19
.4 .5
.17 .18 .19 .20 .21 .22 .23 .24 .25 .26 .27
29
(
)
(IRCT20180103038199N3)
(COVID-19 (IRCT20200607047675N1 ( )
( )
-2019
COVID-19:
19-
-
)
19-
)
(IRCT20200325046859N2) :COVID-19
.31
(Ivermectin) .32 (IRCT20190602043787N3) ( ) (COVID-19) 19 .33 (IRCT20190406043175N3) COVID-19 .34 (IRCT ) : (COVID-19 (IRCT20200522047542N1 .35 .36 :( ) (IRCT20081019001369N7) (IRCT20200928048867N1 ) .37 3/2 – .38 (IRCT
:COVID-19 19-
A
(IRCT20170117032004N3) (IRCT20160310026998N10)
19-
(IRCT20160310026998N11)
2019 ICU
.29 .30
2
(IRCT20200610047722N1) COVID-19
.28
2019
(IRCT20200317046797N1) (IRCT20200324046851N1)
( )
Covid-19
(IRCT20200317046797N2) (IRCT20180802040678N4) 2019 (IRCT20200317046797N3)
((IRCT20140617018126N2
.1 .2 .3 .4 .5 .6 .7 .8 .9
-2019
30
covid-19
)
:COVID-19
(Tocilizumab) IL-6 (IRCT20200406046968N1) (IRCT (IRCT20200317046797N4)
19-
(IRCT20091012002582N21) COVID-19
.10 .11 .12 .13 .14
(IRCT20200406046968N2) ( ) COVID-19 (zifron) 1 .15 (IRCT20200406046968N3) (IRCT20190618043923N4) Covid19 .16 (HA330 (IRCT20200317046797N5 19.17 .18 (IRCT20200503047280N1) : – .19 (IRCT20200518047497N1) :COVID-19 .20 (IRCT ) 19: COVID-19 .21 (IRCT20090609002017N35) 19.22 (IRCT ) (IRCT20200522047545N1) :19 .23 (tPA) .24 (IRCT20200515047456N1) 19 19.25 (IRCT20200317046797N6) ( ) .26 (IRCT20200525047570N1) :COVID-19 .27 (IRCT20200518047497N2) 19 (SVF) .28 (IRCT ) / 19 .29 (IRCT20190312043030N2) 2019 .30 (IRCT )
31
-2019
19
(IRCT20091012002582N22)
.31
Verification of the efficacy of bromhexine hydrochloride in PREVENTION of COVID19 symptomatic .32 (disease. (IRCT20200818048444N1,IRCT20200317046797N7
(Tocilizumab)
COVID-19
) COVID-19
(IRCT20151227025726N13) (IRCT
-1 (IRCT
)
:
(IRCT
19
) (COVID-19)
COVID-19
(IRCT20150107020592N25)
COVID-19
(IRCT20150107020592N29) COVID-19
(IRCT20150107020592N24) COVID-19
.1 .2 .3 .4 .5 .6 .7 .8
(IRCT20151227025726N18,IRCT20150107020592N27) (IRCT20150107020592N23) 19: .9 :19 .10 (IRCT20190810044500N5) (IRCT ) COVID-19 .11 19 favipiravir .12 (IRCT20150107020592N30) COVID-19 Sitagliptin .13 (IRCT20200420047147N1) COVID19 Favipiravir .14 (IRCT20150107020592N26) .15 (IRCT20200209046427N1) COVID-19 (IRCT ) (COVID-19) .16 (IRCT20150107020592N22) .17 EVLW 19 Borage based .18 (IRCT20150107020592N28) 19.19 (IRCT20150725023332N3)
32
-2019
(COVID-19) (IRCT
(IRCT20151227025726N17)
) covid _19
.21 .22
low dose
(IMT)
(IRCT20200611047727N1)
(
COVID-19
.20
19
)
(IRCT20150303021315N19)
COVID 19
) COVID-19
: (IRCT
19
(IRCT20190727044343N1)
) 2019
(IRCT20131129015584N2) COVID-19 19 )
(
:ICU 1
19
(IRCT :2019
(
.24
(IRCT20180712040446N2) COVID-19 Photobiomodulation (PBM) .25 (IRCT20200616047799N1) (IRCT ) COVID-19 .26 COVID-19 (IVIG) .27 ((IRCT20151227025726N20) .28 (IRCT20191211045691N1) COVID-19 .29 (IRCT ) .30 (IRCT ICU COVID-19 .31 (IRCT20131115015405N4)
:19
(IRCT
.23
) (IRCT20200404046935N1) /
) 19-
( ( ) 19
:
COVID-19
+
(IRCT20190804044429N1) /
)
(IRCT20200403046926N1) ) (IRCT20200328046886N1)
.1 .2 .3 .4 .5 .6 .7 .8 .9
33
(IRCT
) COVID-19
-2019
Dimethyl Fumarate
COVID-19
(IRCT20190727044343N2)
19
(IRCT20200411047016N1) 19 (IRCT20131129015584N3) COVID-19 :COVID-19
)
(IRCT (IRCT
)
:
(
(IRCT20200411047030N1)
)
(
) (IRCT
:COVID-19
)
COVID-19
(IRCT
(
) 1399
(IRCT
) COVID-19 (IRCT ) COVID-19
)
)
1398
19
Stopcivir
(BER)
:19
(IRCT
COVID-19
(IRCT
) 19/(
/
(IRCT20200328046886N2)
)
/(
)
/
(IRCT )
/
COVID-19
/
) ( 19-
(IRCT20200913048708N1)
(
COVID-19
)
(IRCT20200316046792N1)
(MSCs)
(IRCT20140528017891N8) (IRCT20200410047009N1) COVID-19 COVID19
Outcome
(Ipecac) (IRCT
)
19
ARB ACEI
(IRCT
) 1398-99 2
(IRCT20140907019073N4) 19
.10 .11 .12 .13 .14 .15 .16 .17 .18 .19 .20 .21 .22 .23 .24 .25
.1 .2 .3 .4 .5 .6
34
-2019
:
(IRCT20161204031229N3) 19-
(IRCT20200318046812N1) COVID-19
(IRCT20190122042450N4)
:COVID 19
(IRCT
: COVID-19 " " "
/
+
+
+
) (IRCT20180725040596N2)
+ "
" +
" 19
(IRCT
:19
+ )
A
(IRCT20200405046951N1)
COVID-19
N-Acetyl Cysteine
:
(IRCT20200623047897N1)
(IRCT20200505047305N1) (IRCT (IRCT
:COVID-19
) 19 ) covid 19 (IRCT
)
(IRCT
(IRCT " (IRCT
) covid19
" " (
" (IRCT
.10 .11 .12
.13 .14
.15
.19 )
.20
(IRCT20200913048701N1)
:COVID-19
.9
COVID19
:
( )
.8
.16 .17 .18
COVID-19
2019
.7
) ) SNP
)
.21 .22 .23
35
19
(IRCT
-2019
.1
) :2019
(IRCT20200310046736N1)
(IRCT
) COVID-19
TNF-
TGF
IL-1, IL-6
IFN-
2019
(IRCT20200404046937N2)
2019
.2 .3 .4 .5
(IRCT20200404046937N1) COVID19
Tranilast (IRCT20200419047128N1)
Chloroquine Kaletra
.7
Tenofovir (COVID-19) (IRCT20200422047168N1)2019
COVID19 (IRCT20200419047128N2) Covid19
(IRCT
)
COVID19 (IRCT20200112046089N1) Ivermectin
COVID-19) 2019)
(19
.8 .9 .10 .11 .12
COVID-19 (IRCT20200519047510N1) Chloroquine Kaletra
.6
Chloroquine Kaletra (IRCT20200422047168N2)
)
.13 (IRCT20200404046937N3)
(
COVID-19:
)
.14
(IRCT20200616047792N1)
+
(SARS-covid-
19) (IRCT20200816048422N1) COVID-19: (IRCT20200404046937N4) (IRCT20190226042851N1)
COVID-19
)
2
.18 COVID-19 MMR .19 (IRCT20200802048266N1)
COVID-19:
19
.16 .17
colloide silver nasal spray 10ppm
(IRCT 19
.15
(IRCT20200404046937N5)
(IRCT20200730048253N1)
.20 .21
36
-2019
(IRCT
-
)
.1 .2
(IRCT20130616013690N7)
19
(IRCT
(IRCT20090701002113N2)
.3
)
.4 .5
COVID-19
(IRCT
)
)
COVID-19
(IRCT
(IRCT ) covid-19 (COVID-19 (IRCT20131215015805N2 :19
-
(IRCT
(IRCT
)
-
-
.1
(IRCT20200413047052N1)
COVID-19
)
8
.7 .8 .9
(IRCT20200508047345N1) COVID-19 . . .10 (IRCT20200411047019N1) COVID-19 .11 (IRCT ) covid-19 .12 (IRCT ) 1399 (IRCT ) 19 .13 (Jollab ) .14 ) : (COVID-19) .15 (IRCT ) COVID-19 .16 (IRCT ) COVID-19 Quercetin .17 (IRCT ) :covid-19 / .18
-
:
.6
:
COVID19
(IRCT
.2
37
(IRCT20200427047215N1) 19 (IRCT20180425039414N3) (COVID-19) SARS-cov2 (IRCT20200428047232N1) :
-2019
.3 .4 .5 .6
E C COVID19
-
:
(IRCT20121216011763N46)
.7
Covid-19
(IRCT
(IRCT20180425039414N2) covid 19 COVID-19 (
(IRCT20200428047229N1)
(IRCT20181208041886N1) COVID-19 : :(COVID-19)
(IRCT
(
(IRCT20200923048815N1)
)
(IRCT20200806048318N1) 19-
19-
(IRCT
19 :(covid-19
(IRCT
)
.10 .11 .12 .13 .14 .15
) (IRCT
)
.8 .9
)
19-
)
)
.16
) (IRCT
)
.17
-
.1
(IRCT20170611034452N11) (COVID 19) (IRCT20101219005416N2) (IRCT20180923041093N4) (COVID_19)
(COVID_19)
(IRCT20180923041093N3) COVID-19
(IRCT
) 99-98
.2
.3 .4 .5
38
-2019
.6
(IRCT20140911019125N6) 19 (IRCT20160313027033N2)
.7
19
.8
COVID-19 I
(
COVID-19
(IRCT
)
.9
(IRCT20200330046899N1)
19
.10
Ivermectin
(IRCT
(IRCT20101219005416N3) 19
(IRCT
)
)
.11
(COVID 19) (IRCT20161108030776N3) (IRCT20140911019125N8) 3 2
) 19-
- – 19
.1
Covid-19
-( ) )
(IRCT 3
)
(IRCT20180922041089N4)1399
(
)
) COVID-19
.2
(
COVID 19
(IRCT
.13 .14
-
.12
.3
PASI % 75
.4
(IRCT20200630047962N1)
)
(IRCT
)
(
)
.5
(
COVID 19
.6 .7
(IRCT20100228003449N31) COVID-19
:( COVID-19) 19 (IRCT20201015049030N1)
-
COVID-19 (IRCT20201004048922N1)
) COVID-19
:
19 (IRCT
.8 .9
39
-2019
(IRCT
)
( COVID-19 ):
(IRCT
)
.10 .11 .12
Covid-19
(IRCT
) 1399
.1
ICU
(IRCT
)
(IRCT20200404046934N1) COVID-19
19 19
(IRCT20160118026097N5) (IRCT20160118026097N4)
-
-
19-
(IRCT
(IRCT20160118026097N3)
(IRCT
A (IRCT20200314046774N1)
) 1399
Covid-19
) Covid-19
(
Covid-19 :
)
.2 .3 .4 .5 .6 .7 .8 .9
(IRCT20180513039641N2)
(IRCT
) 19
.10 .11 .12
fennel - terminalia chebula
(IRCT
)
(IRCT
)
19-
(IRCT20120215009014N353) (IRCT20200426047206N1) 19
.1 .2 .3
NBS
(IRCT20120215009014N354)
COVID-19:
(IRCT20120215009014N355)
.4
COVID-19:
.5
COVID-19: (IRCT20170117032025N7)
19-
(IRCT20200426047206N2)
.6 .7
COVID-19 : (IRCT20200426047206N3)
40
-2019
.8
COVID-19 (IRCT20200902048598N1)
(IRCT
)
19COVID-19 : (IRCT20200426047206N4)
(IRCT
) COVID-19
.11
COVID-19
(IRCT20151228025732N51) Convalescent Plasma
(IRCT20151228025732N53)
19 :
(IRCT20151228025732N52)
1000
-
(IRCT
»
)
(IRCT20200115046144N2)
(IRCT20171213037866N2) 19COVID-19
(IRCT20200402046917N1) (IRCT20160808029264N9)
(IRCT
19
:COVID-19 :COVID-19
.3
.5 .6 .7
Covid-19
(IRCT
.9
)
)
: (IRCT
(IRCT20200506047323N2) (IRCT20200506047323N1)
(IRCT20200509047364N1) COVID-19
.2
.8
COVID-19
19 -
.1
.4
GCSF
«
:
.9 .10
)
.10 .11
.1 .2 .3
41
-
: (IRCT20200514047445N1) 19-
COVID-
(
)
/
(IRCT20200506047323N3) :COVID-19 :COVID-19 (IRCT20200509047364N2) COVID-19
)
COVID-19
(IRCT
-2019
.4
19 (IRCT20200611047735N1) .5 .6 :19 .7 (IRCT20200506047323N4) .8 (IRCT20200506047323N5) .9 .10 (IRCT
) 19-
COVID-19
.1 .2
Sofosbuvir/Velpatasvir
Nigella sativa
”Trifluoprazine“
Trachyspermum ammi
(IRCT
) 19
(IRCT20130812014333N145) (MAB98) .3 Colchicum autumnale
” “Lithium Sofosbuvir-Daclatasvir”“ (IRCT20130812014333N147) COVID-19 ( ) FFP (IRCT )
.4 .5
COVID-
(IRCT20190624043993N3) (IRCT20190624043993N2)
(IRCT20200418047121N1) 19
) (COVID19)
COVID-19 COVID-19
50
.7 .8 .9
ARB ACEi
(IRCT
.6
(IRCT20160625028622N1) (IRCT20200505047318N1)
Covid-19
(IRCT20200408046987N1)
.1 .2 .3
42
-2019
19 ) COVID-19
(IRCT
50
) (IRCT
) 1399 (IRCT (IRCT
.4 .5 .6
covid-19
)
(IRCT
:Covid-19
) Covid-19
(IRCT ) ) 2019
(IRCT
(IRCT ) COVID-19 ) COVID-19
COVID-19
(IRCT
(IRCT20200504047298N2) 19 /
.1 .2 .3 .4
/
.5 .6
diphenhydramine compound
.7
19_
Covid-19
.7 .8
(IRCT20200504047298N1) (IRCT20200504047298N3)
(IRCT20200705048013N1) 19
pentoxifylline
-nCoV -2019
.8
.1 (IRCT20180610040049N3) (IRCT20151222025660N2) -nCoV -2019
(IRCT
/
(IRCT20200517047485N1) 1399
)
19 COVID-19
Tocilizumab (IRCT20200510047383N1) Host-Directed Therapy
(IRCT20180519039711N6) COVID-19
(IRCT
(IRCT
)
)
ivig COVID-19
Favipiravir
.2 .3 .4 .5 .6 .7 .8
43
(
-2019
)
+
(IRCT20200324046850N2)
.2 .3
(IRCT20200324046850N3) N
.1
D3
(IRCT20200324046850N1) COVID 19
C (IRCT20200324046850N5)
COVID-19 (IRCT20200326046868N1)
(IRCT
)
COVID-19
:COVID-19
/
(IRCT20200624047908N1) Grapex
(IRCT
)
COVID-19
(IRCT
(IRCT
)
) (1399)
)
) 19 (IRCT20180624040213N2)19-
.8
.1 .2 .3 .4 .5 .6
(IRCT
-1
COVID-19 (COVID-19) 2019
-1 (IRCT
) (1399)
(IRCT20201024049134N1)
(IRCT
) .COVID-19
(IRCT20200503047281N1) COVID-19
(IRCT
) 19 (IRCT20200825048514N1)
) 19 :19
.7 .8
COVID-19
)
.7
(COVID-19)
COVID-19
(IRCT
.5 .6
COVID19
(IRCT
.4
IRCT)
.1 .2 .3 .4 .5
44
-2019
)
19
(IRCT
(IRCT
) 19
.6 .7
(IRCT
) 19
(SARS-COV-2)
(IRCT20140305016852N4) (19-
19-
(IRCT20160706028815N5)
19
(IRCT
:COVID-19
)
3
(IRCT20151226025699N3)
(COVID-19)
)
(IRCT
(
.3 .4 .5
(IRCT20200705048011N1)
:COVID-19
.1 .2
)
)
.6 .7
.1
(IRCT20200405046960N2,IRCT20200405046960N1) COVID-19 COVID-19 (IRCT20200418047126N1) IRCT)
.3 .4
COVID-19 ( -COVID 19
Convalescent Plasma Therapy
:
(IRCT20150808023559N21) COVID-19
BCG
(IRCT
)
Covid-19 (IRCT20170716035126N4)
19-
(IRCT20150808023559N23)
COVID-19
:
(IRCT20160316027081N1) (IRCT20200404046948N1) covid-19
.2
.5 .6 .7
.1
.2
45
19
(IRCT
)
(IRCT
)
(IRCT
)
(IRCT
)
-2019
(IRCT20200406046963N1) covid19
19 19
"
19-
(IRCT20090304001739N3) COVID-19
(IRCT "
(IRCT20130428013151N2) COVID-19 (IRCT20160126026217N4) ) 19 A, D, E, C, B
(IRCT
:
(IRCT 19
(IRCT )
:19-
(IRCT20200416047104N1) covid 19
(IRCT
)
.4 .5
.5
covid-19
(IRCT
.3
.2 .3 .4
covid 19
1
)
.2
.1
COVID-19
)
.4 .5 .6 .7
.1
"
"
.3
)
– .1
Covid-19
(IRCT (IRCT 19
) ( )
( )
(
) .1399
(IRCT
)
)
19
.2 .3
46
-2019
:COVID-19
)
(IRCT
(IRCT20180114038350N3) (COVID 19) 2019 : COVID-19
(IRCT
(IRCT20190415043279N6) 19(IRCT ) 19-
:
COVID- 19
(IRCT20200408046992N1)
:19 -
(IRCT20200413047056N1)
) (IRCT
)
COVID-19
(IRCT ) 19 .COVID- 19
)
(
.4
.1 .2 .3 .4
.1 .2 .3 .4
.1
covid-19
(IRCT
)
COVID-19
(IRCT20200413047062N1)
19 19
(COVID 19 (IRCT20200501047259N1 (IRCT20200501047258N1) 19
(IRCT (IRCT
)
COVID-19
(IRCT20131112015390N5) 1399 (IRCT20181203041832N1) 19-
)
.2 .3 .4
.1 .2 .3 .4
47
-2019
) (IRCT20150303021315N17) ) Covid-19 " " "
/
+
-COVID
(haplo-identical) +
+
NK
(IRCT
+ "
" +
" 19
(IRCT
+
.1 .2 .3
) -
( )
19-
.1
(IRCT
)
:1399 -
COVID-19
(IRCT
) 1398-99
-
.2
( ) .3
(IRCT20201005048936N1) COVID-19
19
(IRCT
) 19
.1 .2 . (IRCT20081011001323N25)
(IRCT
) COVID-19
(
/
)
(IRCT20200418047116N1)
.3
.1
(IVIG) COVID-19:
19-
.2 (IRCT20140407017169N2)
:COVID-19
.3 (IRCT20200408046988N1)
48
-2019
(IRCT
0/2
)
.1
: covid-19
.2
(IRCT20200527047581N1)
)
: covid-19
(IRCT
+
(IRCT
.1
(IRCT20200324046852N1) (PPD) (IRCT20200414047070N1) 1399 -
19
)
.3
.2 .3
:19
.1 (IRCT20200725048199N1)
:19
(IFN -1b)
19
(IRCT
1-
.2
(IRCT ) (Phoenix dactylifera) )
(IRCT
.3
:
) (ARDS)
(IRCT20190418043307N1) COVID-19
(Ficus Carica L)
COVID-19
(IRCT
)
.1 .2 .3
19-
19-
(IRCT
(IRCT20120703010178N20)
) 19 (IRCT
)
.1 .2 .3
49
-2019
19-
(IRCT
) 1399
COVID-19
(IRCT
)
(IRCT -
19
)
.1 .2 .3
.1
120 19-
(IRCT20200831048568N1) 19 800 .2 (IRCT20200128046294N3) 19Sovodak .3 (IRCT ) 99 99
(IRCT20200325046860N1) COVID-19 COVID-19
(IRCT20200525047562N1)
(IRCT20120225009124N4)
.1
: 19
COVID-19
(IRCT20110907007511N4)
: COVID-19
(IRCT20200223046586N2) (DMSO) (IRCT20200727048217N1) COVID-19
19
(IRCT20200415047082N1) COVID-19
/
.1 .2
(IRCT20200412047042N1) 1399
.2
.1 .2
.1 .2
50
-2019
19
(IRCT20200513047426N1)
19
(IRCT20201003048904N1) 1399
(IRCT (IRCT
19
) 1399 ) COVID-19
.1 .2
.1 .2
.1
A
19
(IRCT20180520039738N2) ) .2 (IRCT20200415047089N1)
(
(IRCT
)
COVID-19 COVID-19
(IRCT20200416047099N2)
(safety) ) COVID-19
NK cell
(IRCT
) COVID-19
) ( (IRCT
)(
.1 .2
.1 .2
-
(IRCT
) COVID-19
(IRCT20200105046009N4) COVID-19
.1 .2
51
( )
)
-2019
.1
(IRCT20201003048905N1) 1399
ICU
COVID-19
(IRCT
.2
.1 (COVID19 (IRCT20200718048129N1 :COVID-19
"
" "(Sovodak (sofosbuvir + Daklatasvir)"
.2
(IRCT20200328046885N1)
COVID-19 (IRCT20200609047707N1)
COVID-19 (IRCT20200329046892N1)
(IRCT
)
(IRCT (IRCT
(IRCT
) ) 19 -
) 19 -
(IRCT
19-
-
(IRCT
) 19-
)
-
:
52
-2019
COVID-19
NK
(IRCT
)
(IMBSR)
(IRCT
)
:19
(IRCT20190831044653N5)19-
(IRCT20200405046953N1) (SOLIDARITY
19-
19
4
)
-
intermediate
(IRCT
)
x2 2
19-
(IRCT
) 1399
19-
Hep-S
BCc1
(IRCT20170731035423N2)
(IRCT
(IRCT
(IRCT
) (COVID-19)
)
) Covid-19
(IRCT20200426047212N1)19-
-
53
-2019
:19
(IRCT
)
COVID19
outcome (IRCT20200930048892N1)
Covid-19 (IRCT20180429039463N2)
:COVID-19
Celecoxib
(IRCT20200907048644N1)
-5 2019 . . . 19.
1 .
54
-2019
. .
48
.
-2 .
. 19.
. .
: (ethics.research.ac.ir)
-3
55
.
-2019
1397 .
.
. .
.
20
(ethics@behdasht.gov.ir)
:
-4
. ... .
-6
56
-2019
20 42 .
-7 5536 155 400
1399
18
194
99
18 9
-
9
293
9
274
9
259
9 8
-
252
-
245
-
)
184
8
150
7
138
7
-
136
7
-
133
7
127
7
120
7
-
-
119
6
-
114
6
-
105
6 6
-
401
9
4
68765
96 -
86
https://www.ncbi.nlm.nih.gov/research/coronavirus/, accessed on November 08, 2020
-
57
-
5
83
5
82
4
81
4
81
4
71 -
4
70
-
4
67 -
3
( )
3
66 65
-
3
57 -
3
56
3
56
3
56
3
53
3
51
3
-
49
3
-
44
3
44
3
43
2
-
41 -
2
39
2
39 36
-
-
36
2 2
-
62 -
3
2
-
62
3
2
-2019
(
34 -
33
2
-
28
2
-
25
2
-
25
2
-
24
-
2
21
-
2
20
-
2
20
-
2
18
)
58
-2019
2
17
2
17 -
2 -
2
-
16 16 -
15
1 «
1
»
-
15
1
14
1
14
-
1 1
13
1
12 )
-
12
1
-
12
1
-
11
1
-
11
1
-
11
1
-
11
1
1
11
1
11
1
10
1
10 -
1 1
10
-
-
-
13
-
-
-
-
-
10
5536
9
-
-8 (
)
19 .
(multicentral)
1399
20
SARS-COV-2
6 80
59
-2019
.
(multidisciplinary) http://nimad.ac.ir/content/202/COVID -19-Call
27
286 . 99
30
191399
19
.1
.2 SARS-Cov-2
N
nsp8 nsp3 S .3
SARS-CoV-2 COVID-19
TMPRSS2 ACE-2 .4
COVID-19 HLA HNA LIFT GAT GIFT SARS )
.5
19
(RDT)
.6 (COV2
19
.7 .8
SARS-CoV-2 COVID-19 SARS-CoV-2
.9 .10
-2019
60
19.11 .12
COVID-19
.13
19-
.14
SARS-CoV2 1399- 1398
.15
:
(Coronavirus (COVID-19
COVID-19 :
;1919-
: Covid-19
19-
.16 .17 .18 .19 .20
)
.21
.22
SARS-CoV-2
19RBD
Fc 19
Spike
.23 .24
.25 COVID-19 : 19-
.26 .27
61
-2019
19-
-1
Monitor Health Status to Identify Health Problems .1 .2 19 (IHR) International Health Regulation
.3
)
.4 .5
Diagnose and Investigate Health Problems and Health Hazards .6 .7 .8 Inform, Educate, and Empower People about Health Issues .9 .10 /
.11
.12 – .13
.14 .15 .16 .17 .18 .19 -
.20
Mobilize Community Partnerships to Identify and Solve Health Problems .21
62
-2019
.
.22 .23 .24 .25
Develop Policies and Plans that Support Individual and Statewide Health Efforts .26 .27 .28 .29
(...
)
)...
.30 .31
(
)
.32 .33 .34
19
.35 .36 .37 .38 .39
(
)
.40 .41
20
...
...
.42
63
-2019
.43
.44 .45 ...
.46 .47 .48 .49 .50 .51 Enforce laws .52 .53
Link People to Needed Personal Health Services and Assure the Provision of Health Care When Otherwise Unavailable .54 .55 . .56 .57 .58 .59 .60 .61 .62 .63 .64 .65 .66 .67 Assure a Competent Public and Personal Health Care Workforce .68 .69
ICU
.70 )
.71 .72
64
-2019
)
.73
.
.74 .75 .76
Evaluate Effectiveness, Accessibility, and Quality of Personal and Population-Based Health Services .77 ...
.78 .79 .80
.81 /
/
.82
/
whole university approach
.83 .84 .85
:
.86 :
–
.87 .88
Published on Nov 24, 2020
براساس نسخه هفتم گزارش معاونت تحقیقات و فناوری وزارت بهداشت، درمان و آموزش پزشکی، منتشره در تاریخ ۲۰ آبان ۱۳۹۹، که نسخه ای از آن در اختیار «...
Published on Nov 24, 2020
براساس نسخه هفتم گزارش معاونت تحقیقات و فناوری وزارت بهداشت، درمان و آموزش پزشکی، منتشره در تاریخ ۲۰ آبان ۱۳۹۹، که نسخه ای از آن در اختیار «...